GSA Capital Partners’s Kiniksa Pharmaceuticals KNSA Stock Holding History

GSA Capital Partners’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$717K	Sell	11,219 -38	-0.3%	-$1.97K	0.05%	750
2026 Q1	$542K	Sell	11,257 -57,737	-84%	-$2.56M	0.03%	864
2025 Q4	$2.85M	Sell	68,994 -8,990	-12%	-$361K	0.25%	27
2025 Q3	$3.03M	Buy	77,984 +57,566	+282%	+$1.87M	0.25%	20
2025 Q2	$565K	Buy	+20,418	New	+$520K	0.04%	836
2024 Q4	–	Sell	-10,729	Closed	-$268K	–	1824
2024 Q3	$268K	Buy	+10,729	New	+$261K	0.02%	1278
2023 Q4	–	Sell	-63,216	Closed	-$1.1M	–	1718
2023 Q3	$1.1M	Buy	63,216 +28,468	+82%	+$480K	0.09%	346
2023 Q2	$489K	Buy	34,748 +4,613	+15%	+$61.7K	0.05%	754
2023 Q1	$324K	Buy	+30,135	New	+$397K	0.03%	986
2022 Q1	–	Sell	-16,157	Closed	-$190K	–	1624
2021 Q4	$190K	Buy	+16,157	New	+$199K	0.02%	1241
2020 Q4	–	Sell	-20,774	Closed	-$318K	–	1420
2020 Q3	$318K	Buy	+20,774	New	+$390K	0.05%	690

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

GSA Capital Partners's KNSA Position: Q2 2026 in Review

GSA Capital Partners reduced its Kiniksa Pharmaceuticals (KNSA) stake by 0.34% in Q2 2026, selling an estimated $1.97K and leaving 11,219 shares worth $717K. The position accounts for 0.05% of the portfolio, ranked #750.

GSA Capital Partners first reported a position in KNSA in Q3 2020 and has held it in 11 quarters since. The position peaked at $3.03M in Q3 2025. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

GSA Capital Partners held 11,219 shares of Kiniksa Pharmaceuticals worth $717K as of Q2 2026.
GSA Capital Partners sold 38 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $1.97K.
Kiniksa Pharmaceuticals made up 0.05% of GSA Capital Partners's portfolio in Q2 2026, its #750 holding.
GSA Capital Partners first reported a position in Kiniksa Pharmaceuticals in Q3 2020 and has held it in 11 quarters since.
GSA Capital Partners's Kiniksa Pharmaceuticals position peaked at $3.03M in Q3 2025.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.